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individual institution level to improve prevention, screening, and treat-
ment efforts.
C8-04 Epidemiology & Tobacco Control, Wed, 10:30 - 12:15
Genetic polymorphisms in cell cycle control pathways and lung 
cancer risk
Lu, Charles; Spitz, Margaret R.; Yang, Hushan; Wang, Wei; Stewart, 
David J.; Wu, Xifeng 
UT M.D. Anderson Cancer Center, Houston, TX, USA
Background: Cell cycle checkpoint function is crucial for the preven-
tion of carcinogenesis in mammalian cells. To test the hypothesis that 
common sequence variants of genes in the cell cycle control pathway 
may affect lung cancer predisposition, we explored the associations of 
11 polymorphisms in seven cell cycle control genes with lung cancer 
risk. 
Methods: We conducted a case-control study in Caucasians that in-
cluded 1,518 lung cancer patients and 1,518 controls. 
Results: Our results showed that when individuals with at least one 
variant allele were compared to homozygous wild-type carriers, a sig-
niﬁcantly increased lung cancer risk was identiﬁed for polymorphisms 
in p53 intron 6 (rs1625895) (odds ratio [OR] = 1.29, 95% conﬁdence 
interval [CI] 1.08-1.55) and in p27 5’ untranslated region (rs34330) 
(OR = 1.27, 95% CI 1.01-1.60). Compared with the homozygous 
wild-types, the homozygous variant F31I genotype (TT) of the STK15 
gene was associated with a signiﬁcantly reduced risk for lung cancer 
(OR=0.58, 95% CI = 0.37-0.90). The AA genotype of CCND1 G870A 
was associated with a signiﬁcantly increased risk (OR = 1.26, 95% 
CI 1.03-1.53) when compared with genotypes containing at least one 
wild-type allele. In an attempt to assess the combined inﬂuence of all 
the investigated polymorphisms on lung carcinogenesis, we found that 
compared to the reference group with one variant allele, individuals 
with two (OR = 1.53, 95% CI 0.97-2.41) and three or more (OR = 1.59, 
95% CI 1.07-2.34) variant alleles exhibited increasing risk of lung 
cancer with a gene dosage effect (P for trend = 0.041). This pattern was 
more evident in ever smokers (P for trend = 0.037), heavy smokers 
(P for trend = 0.020), and older subjects (P for trend = 0.011). Higher 
order gene-gene interactions were evaluated using the classiﬁcation and 
regression tree (CART) analysis, which indicated that STK15 F31I and 
p53 intron 6 polymorphism might be associated with lung carcinogen-
esis in never/light-smokers and heavy smokers, respectively. 
Conclusions: This is the ﬁrst study using a polygenic strategy to 
elucidate the inﬂuences of a panel of cell cycle genetic polymorphisms 
on lung cancer risk. Our results suggest that cell cycle gene polymor-
phisms and smoking may function collectively to modulate the risk of 
lung cancer.
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Background: RCTs on lung cancer treatment are increasing rapidly. 
Many meta-analyses were performed to synthesize and clarify their 
results. Even if the meta-analyses represent the high level of proof, 
their quality is variable. This review attempts to identify meta-analyses 
of RCTs studying lung cancer treatment, to assess their quality and to 
identify criteria of good quality. 
Methods: A systematic research was performed using PubMed, 
EMBASE, Cochrane, Web of knowledge, and American Society of 
Clinical Oncology databases, for 1990-2006, with the following search 
terms: lung cancer, meta-analysis and systematic review. There were no 
language restrictions. Meta-analyses of RCTs on lung cancer treatment 
published as full paper were eligible. Two investigators independently 
selected the publications. When the same results were reported in 
more than one publication, the evaluation was based on a combina-
tion of all available information. Data on meta-analysis characteristics 
(publication, size, methods…) were extracted by 2 investigators. After 
a learning period, each meta-analysis was evaluated independently by 
3 reviewers using the Oxman and Guyatt index and with the scoring 
method proposed by Sacks et al. Disagreements were resolved by dis-
cussion. The clinical relevance was evaluated by 2 clinicians. Quality 
criteria were identiﬁed by discriminant analysis through 3 groups of 
meta-analyses deﬁned by their quality score (poor, middle, high). We 
also compared the reports evaluating the same intervention.
Results: A total of 1,723 articles were retrieved by the initial search. 
Fifty-nine articles were considered to be eligible for assessment. Nine 
articles corresponded to update or duplicate papers of previous publica-
tions leading to 50 distinct projects. The 50 projects reported 70 meta-
analyses. 88% of reports were published in English. The articles were 
published between 1992 and 2006, 54% after 2003. 10% of articles 
were published by authors of the Cochrane Collaboration. The median 
numbers of trials and patients per project were 11 (3-57) and 2,094 
(360-11,160) respectively. 12.5% of meta-analyses were based on in-
dividual patient data. Among the 70 meta-analyses, 76% concerned the 
non-small cell lung cancer (NSCLC), 23% the small cell lung cancer 
(SCLC) and 1% lung cancer in general. 49 meta-analyses evaluated 
chemotherapy (7 in early NSCLC, 7 in locally advanced NSCLC, 16 
in advanced NSCLC, 14 in several stages of NSCLC and 5 in differ-
ent stages of SCLC), 12 radiotherapy (1 in early NSCLC, 2 in differ-
ent stages of NSCLC, 6 in limited SCLC and 3 in different stages of 
SCLC), 2 the association of chemotherapy and radiotherapy in locally 
advanced NSCLC, 1 surgery in early NSCLC and 6 other treatments 
(immunotherapy, Chinese herbs). For 11 therapeutic questions, more 
than 2 meta-analyses were performed. Analysis on quality evaluation is 
ongoing. 
Conclusion: A large number of meta-analyses of RCTs on lung cancer 
treatment had been published in the recent years, including several on 
the same topic. Their usefulness need to be studied. The assessment 
of the quality of meta-analyses and the comparison of reports on the 
same topic could permit to help clinicians and decision-makers in their 
practice. 
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Impact of a graphic health warnings tobacco campaign in Australia
Bishop, James F.1 Cotter, Trish2 Perez, Donna2 Dessaix, Anita2 
1 Cancer Institute NSW, Alexandria, NSW, Australia 2 Cancer Institute 
NSW, Sydney, NSW, Australia 
Survey evidence from ex-smokers has repeatedly afﬁrmed that person-
alised concern about health consequences is the primary motivation 
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ascribed to smoking cessation. Seven new warnings were introduced on 
tobacco products in Australia in March 2006 and a second set intro-
duced in November 2006 including graphic images of health effects 
such as peripheral vascular disease, mouth and throat cancer, lung can-
cer and stroke. A $10M AUD campaign strategy was developed in New 
South Wales (NSW). It included a mass media campaign designed to 
increase the likelihood of smokers making a successful quit attempt by:
a) adding depth, meaning and personal relevance to the new pictorial 
health warnings and 
b) maintaining the impact of the warnings far beyond the anticipated 
newsworthiness of their initial introduction.
The health warnings campaign was launched in May 2006 and focused 
on the graphic images of peripheral vascular disease (amputation) and 
mouth and throat cancer. The campaign was supported by complemen-
tary research driven media messages about smoker’s self exempting 
beliefs and the health consequences of their excuses. In addition, to 
maximise the chance of the intended behavioural response smokers 
need accessible and reliable services to help them quit. A Quitline 
services campaign was also run to promote the smokers’ help-line that 
focused on support for smokers on topics such as planning a quit at-
tempt, nicotine replacement therapy and cravings.
Calls to the Quitline (smokers’ help-line) more than doubled from 
27,000 in 2005, to 57,000 in 2006, increasing to an average monthly 
call rate of 5,000 and peaking at 9,400 in the month of May 2006. 
Campaign tracking research showed a high awareness of the “amputa-
tion” and “mouth cancer” advertising and the graphic warnings on 
packs. Call response was closely associated media weight and to recall 
of the graphic warnings campaign. In the year 2006, smoking preva-
lence in NSW adults (aged 16 years and over) showed the largest drop 
ever recorded the previous average decline was 0.5% per year over 
ten years. Smoking prevalence has declined from 20.1% in 2005 to 
17.7% overall in 2006 (daily and occasional smoking). The decline was 
greater among males with 15% of males reporting daily smoking (down 
2.5%) and 12.9% of females reporting daily smoking (down 1.2%). 
In NSW this fall represents around 76,800 smokers (age-adjusted) 
who have reported quitting in 12 months. In addition, smoking rates 
amongst teenagers were at the lowest rate in 20 years indicating social 
norms around smoking are shifting. Graphic warnings on tobacco 
products, supported by well-funded mass media campaigns and an ap-
propriate legislative framework, have led to dramatic falls in smoking 
prevalence in NSW.
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Survival rates for lung cancer patients in the UK are below those of 
most western countries. and there is a four-fold difference in the 5yr 
survival rate between the best and worst performing areas of the coun-
try. We do not understand the reasons for these differences and how 
best to correct them. The National Lung Cancer audit (LUng CAncer 
DAta) programme for England (and Wales) has been established to 
provide the mechanism for the ongoing collection and analysis of data 
to try and answer some of these questions and to steer service improve-
ment. The programme is currently commissioned by the Healthcare 
Commission and managed within the Information Centre for Health 
and Social Care in partnership with the Royal College of Physicians. 
LUCADA began collecting data in 2004 (with 2005 being the ﬁrst full 
year) and as at 28.2.07 had 35,027 patient records on the database. We 
estimate that for 2006 this will include nearly 60% of the incident cases 
in England. The ﬁrst annual report was published in December 2006 
and contained data on all cases of lung cancer with an initial date of 
referral in 2005. This abstract describes some data from that popula-
tion, but by in September 2007 we will be in a position to report to 
the World Lung Cancer Conference on the 2006 data. By the end of 
February 2007 >90% of the eligible hospitals from all 34 of the English 
Cancer Networks had submitted data. For the 10,920 cases of lung 
cancer diagnosed in 2005 the median age was 72 (range 18-101): 6584 
males and 4336 females. Only 57% of these cases had a conﬁrmed 
tissue diagnosis (interquartile range by cancer network: 48%-73%; 
median 63%). 78% of patients were reviewed by a multi-disciplinary 
team (interquartile range: 70%-92%; median 82%). 8.6% underwent 
surgical resection (interquartile range: 4.4%-10.8%; median 6.9%) and 
only 43% of patients received any active-cancer treatment (interquartile 
range: 35%-63%; median 48%). These values are low by international 
standards and demonstrate signiﬁcant regional variation across Eng-
land. Incomplete data collection can probably, at least in part, explain 
these apparently low rates. By collecting data on case-mix variables 
such as postcode (and therefore deprivation status), age, cell type, 
performance status, co-morbidity and stage at presentation, the Na-
tional Lung Cancer Audit programme intends to carry out risk-adjusted 
analyses which, it is hoped, will start to explain some of the variations 
in practice and outcomes. The data from 2005 was not of a sufﬁciently 
high standard of completeness to allow for this, but we are hopeful that 
this will be possible on 2006 data from at least a proportion of centres.
The National Lung Cancer Audit continues to recruit steadily and is 
now, we believe, the largest audit of lung cancer services ever attempt-
ed. The continuing aim is to encourage participation with comprehen-
sive data collection so that risk adjusted comparative data on activity, 
performance and outcomes becomes regularly available with the aim of 
improving patient outcomes for the future. 
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Background: Cytologic approaches such as pleural lavage cytology 
(PLC) are considered as aids to assessing prognosis of lung cancers. 
However, there is some controversy whether radical surgery is war-
ranted based on the positive PLC ﬁndings with early-stage non-small 
